Skip to main content
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.
What are you looking for?

Hybrid Decentralized Trials in Oncology: A Path to Diversity

During the pandemic, oncology research teams around the world embraced decentralized clinical trials (DCTs) to keep patients and investigators safe. But in the purest sense, a “siteless” decentralized trial may not be suited to the majority of cancer patients receiving investigational therapies. The solution is a hyhbrid DCT model, which can reduce logistical burdens that disproportionately affect diverse and/or economically disadvantaged communities. Download the paper to learn the advantages of hybrid DCTs in oncology from the patient’s viewpoint, the regulatory and technology shifts that favor these strategies and the social/cultural contexts that will affect such trials going forward.


Download the article below

To download the free whitepaper, fill out the form below:

Interested in Syneos Health?